



**Maidstone and
Tunbridge Wells**
NHS Trust

Ref: FOI/GS/ID 7197

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

03 March 2022

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to intra-vitreous injections or implants.

You asked:

1. For the 4-month period from September to December 2021, how many patients has your trust treated (using intra-vitreous injections or implants) for each of the following eye conditions:

- 1. Wet Age-Related Macular Degeneration (wAMD)*
- 2. Diabetic Macular Oedema (DMO)*
- 3. Retinal Vein Occlusion - Central (CRVO) or Branch (BRVO)*
- 4. Any other eye condition*

2. How many of the following intra-vitreous injections/implants has your trust administered in the four-month period from September to December 2021:

- 1. Aflibercept*
- 2. Bevacizumab*
- 3. Brolucizumab*
- 4. Dexamethasone*
- 5. Fluocinolone acetonide*
- 6. Ranibizumab*

3. Please provide the number of injections/implants by eye condition for the four-month period from September to December 2021.

Number of Injections/Implants: Sep to Dec 2021

Eye Conditions – wAMD, DMO, RVO

Treatment -

Aflibercept

Bevacizumab

Brolucizumab

Dexamethasone

Fluocinolone acetonide

Ranibizumab

Trust response:

The attached and linked report can be used to answer the questions.

Please note: Pharmacy Reporting is now by financial month/quarter/year.



April 2021-March
2022 Ophthalmology